Order Article Reprints

Ciardiello D, Napolitano S, Famiglietti V, Esposito L, De Falco V, Di Liello A, Avallone A, Maiello E, Pietrantonio F, Cremolini C, et al. Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials. Cancers. 2023; 15(7):2117. https://doi.org/10.3390/cancers15072117

Ciardiello, Davide, Stefania Napolitano, Vincenzo Famiglietti, Lucia Esposito, Vincenzo De Falco, Alessandra Di Liello, Antonio Avallone, Evaristo Maiello, Filippo Pietrantonio, Chiara Cremolini, and et al. 2023. "Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials" Cancers 15, no. 7: 2117. https://doi.org/10.3390/cancers15072117

Ciardiello, D., Napolitano, S., Famiglietti, V., Esposito, L., De Falco, V., Di Liello, A., Avallone, A., Maiello, E., Pietrantonio, F., Cremolini, C., Zampino, M. G., Fazio, N., Troiani, T., Martinelli, E., Ciardiello, F., & Martini, G. (2023). Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials. Cancers, 15(7), 2117. https://doi.org/10.3390/cancers15072117